The safety and efficacy of tyrosine kinase inhibitors against EGFR in patients with glioma; A systematic review, meta-analysis, and sub-group analysis on glioblastoma
OncologiaSobre o estudo
- Desenho
- Metanálise
- Nível de evidência
- 1 · Evidência consolidada
- Revista
- Journal of clinical neuroscience : official journal of the Neurosurgical Society of Australasia
- Publicado em
- 28 fev 2025
- Citações
- 9
O resumo deste estudo é do publisher e não tem licença aberta: por isso mostramos aqui só os dados do estudo, e o texto fica na fonte original, nos links abaixo.
O estudo original
The safety and efficacy of tyrosine kinase inhibitors against EGFR in patients with glioma; A systematic review, meta-analysis, and sub-group analysis on glioblastoma
Mohammad Amin Habibi, Muhammad Hussain Ahmadvand, Pouria Delbari, Mohammad Sina Mirjani, Amir Hessam Zare, Baran Mehdizadeh, Ali Allahdadi, Zahra Ardestani, Romina Hamidi Rad, Aliakbar Aliasgary et al.
Descritores MeSH
- Antineoplastic Agents
- Brain Neoplasms
- Protein Kinase Inhibitors
- Glioblastoma
- Glioma
- ErbB Receptors
- Humans
- Treatment Outcome
- Tyrosine Kinase Inhibitors
Veja também
Estudos relacionados
- Targeting EGFR in glioblastoma: lessons from a disappointing journey. A systematic review
- The safety and efficacy of VEGFR tyrosine kinase inhibitors for patients with gliomas: a systematic review, meta-analysis, and a specific analysis on glioblastoma
- Hemorragia intratumoral e intracraniana associada à terapia alvo da PAMK: revisão sistemática e síntese mecanicista
- The clinical benefit of adding anlotinib to chemoradiothearpy in high-grade gliomas: a systematic review, meta-analysis, and specific analysis on glioblastoma